Skip to main content
Log in

Marked Q-T prolongation due to encainide therapy

  • Clinical Studies
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Encainide is a type Ic antiarrhythmie agent. During encainide therapy, mild Q-T interval prolongation can be seen, usually associated with prolongation of the Q-R-S interval. The present case report describes an unusual and marked prolongation of the Q-T interval with no Q-R-S interval prolongation in a patient who was treated with encainide for atrioventricular nodal reentrant tachycardia. The drug metabolite profile in this patient's serum indicated an unusual elevation of the 3-methoxy-O-demethyl encainide metabolite, versus O-demethyl encainide. This elevated metabolite level suggests that 3-methoxy-O-demethyl encainide has a significant effect on prolongation of repolarization. An abnormal metabolism of encainide may be the underlying mechanism by which some patients would manifest an unusual prolongation of Q-T interval during encainide therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Roden DM, Reele SB, Higgins SB, et al. Total suppression of ventricular arrhythmias by encainide. N Engl J Med 1980; 302: 877–882.

    Google Scholar 

  2. Kesteloot H, Stroobandt R. Clinical experience with encainide (MJ 9067) a new antiarrhythmic drug. Eur J Clin Pharmacol 1979; 16: 323–326.

    Google Scholar 

  3. Abdollah H, Brugada P, Green M, et al. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. Am J Cardiol 1984; 54: 544–549.

    Google Scholar 

  4. Carey ELJR, Duff HJ, Roden DM, et al. Encainide and its metabolites. J Clin Invest 1984; 73: 539–547.

    Google Scholar 

  5. Gren GB, Varghese PJ, Katz RJ, Ross AM. Arrhythmogenicity of encainide. The role of QT interval (abstr), Am J Cardiol 1981; 47: 498A.

    Google Scholar 

  6. Chesnie B, Podrid P, Lown B, Raeder E. Encainide for refractory ventricular tachyarrhythmia. Am J Cardiol 1983; 52: 495–500.

    Google Scholar 

  7. Conrad GJ, Ober RE. Metabolism of flecainide. Am J Cardiol 1984; 53: 41B-51B.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, W., Jazayeri, M. & Tchou, P. Marked Q-T prolongation due to encainide therapy. Cardiovasc Drug Ther 2, 283–286 (1988). https://doi.org/10.1007/BF00054634

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054634

Key words

Navigation